Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
PRME vs TEVA — Stock Comparison
Compare PRME and TEVA side-by-side on StoQuant: PRME Q-Score 50 vs TEVA 68; analyst signal 69 vs 81. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- PRME — Prime Medicine Inc. Common Stock · Health Care · market cap $685M · Q-Score verdict Hold (50.0, grade C) · analyst signal 69/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 94/100, analyst consensus 76/100 · weakest signals: technicals 12/100. Full PRME research.
- TEVA — Teva Pharmaceutical Industries Limited · Health Care · market cap $45.30B · Q-Score verdict Buy (68.0, grade B) · analyst signal 81/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 92/100, technicals 92/100 · weakest signals: competitive moat 76/100. Full TEVA research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: PRME research · TEVA research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →